Mechanism of gut microbiota and Axl/SOCS3 in experimental autoimmune encephalomyelitis

Area of Science:

• Neuroscience
• Immunology
• Microbiology

Background:

• Multiple sclerosis (MS) is an immune-mediated central nervous system (CNS) disease.
• Experimental autoimmune encephalomyelitis (EAE) serves as a model for studying MS pathogenesis.
• The gut microbiome's influence on CNS autoimmunity is an area of active research.

Purpose of the Study:

• To investigate the role of intestinal microbiota in the development of EAE in mice.
• To identify specific microbial changes associated with MS-like pathology.
• To explore potential therapeutic targets within the gut microbiome for MS.

Main Methods:

• Induction of EAE in C57BL/6 mice, divided into control and EAE groups.
• Monitoring of body weight and neurological function scores.
• Quantification of IL-17 and IFN-γ levels via ELISA.
• Analysis of mRNA expression for AXL and SOCS3 using real-time PCR.
• 16S rRNA gene sequencing to analyze gut microbial composition at various time points.

Main Results:

• EAE induction led to decreased body weight and neurological symptoms.
• Elevated IL-17 and IFN-γ levels peaked at day 21 in the EAE group.
• AXL and SOCS3 expression decreased initially, then increased.
• Significant alterations in specific bacterial groups, including *Alistipes*, *Blautia*, *Lachnospiraceae*_NK4A136_group, *Allobaculum*, *Eubacterium*, and *Helicobacter*, were observed at different time points.
• The *Prevotellaceae*_NK3B31_group was identified as a potential key contributor to MS development.

Conclusions:

• Gut microbiota composition is significantly altered during EAE development.
• Specific bacterial taxa are associated with MS pathogenesis.
• Targeting and regulating intestinal microbiota presents a promising new therapeutic avenue for multiple sclerosis.